Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 27, 2014, Pages 9977-9982

  Lohr, Kelly M ^a   Bernstein, Alison I ^a   Stout, Kristen A ^a   Dunn, Amy R ^a   Lazo, Carlos R ^a   Alter, Shawn P ^a   Wang, Minzheng ^a   Li, Yingjie ^a   Fan, Xueliang ^b   Hess, Ellen J ^b   Yi, Hong ^c   Vecchio, Laura M ^d   Goldstein, David S ^e   Guillot, Thomas S ^a   Salahpour, Ali ^d   Miller, Gary W ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Fast scan cyclic voltammetry; Norepinephrine; Serotonin; SLC18A2

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BASAL GANGLION; BRAIN DAMAGE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINE RELEASE; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPSE VESICLE;

FAST-SCAN CYCLIC VOLTAMMETRY; NOREPINEPHRINE; SEROTONIN; SLC18A2;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CORPUS STRIATUM; DOPAMINE; MICE; MICE, TRANSGENIC; PARKINSONIAN DISORDERS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84904012715     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1402134111     Document Type: Article

References (58)

1. Carlsson A (1972) Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl 51:11-42.
2. Freis ED (1954) Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 251(25):1006-1008.
3. Eisenberg J, Asnis GM, van Praag HM, Vela RM (1988) Effect of tyrosine on attention deficit disorder with hyperactivity. J Clin Psychiatry 49(5):193-195.
4. Song CH, Fan X, Exeter CJ, Hess EJ, Jinnah HA (2012) Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia. Neurobiol Dis 48(1):66-78.
5. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192(4238):481-483.
6. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1988) Cocaine self-administration appears to be mediated by dopamine uptake inhibition. Prog Neuropsychopharmacol Biol Psychiatry 12(2-3):233-239.
7. Klawans HL, Jr., Goodman RM, Paulson GW, Barbeau A (1972) Levodopa in the presymptomatic diagnosis of Huntington's chorea. Lancet 2(7766):49.
8. Erickson JD, Eiden LE, Hoffman BJ (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA 89(22):10993-10997.
9. Erickson JD, Eiden LE (1993) Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J Neurochem 61(6):2314-2317. (Pubitemid 23354095)
10. Liu Y, Roghani A, Edwards RH (1992) Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA 89(19):9074-9078.
11. Sulzer D, Zecca L (2000) Intraneuronal dopamine-quinone synthesis: A review. Neurotox Res 1(3):181-195.
12. Goldstein DS, et al. (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem 126(5):591-603.
13. Alter SP, Lenzi GM, Bernstein AI, Miller GW (2013) Vesicular integrity in Parkinson's disease. Curr Neurol Neurosci Rep 13(7):362.
14. Ben-Shachar D, Zuk R, Glinka Y (1995) Dopamine neurotoxicity: Inhibition of mitochondrial respiration. J Neurochem 64(2):718-723.
15. Mosharov EV, et al. (2009) Interplay between cytosolic dopamine, calcium, and alphasynuclein causes selective death of substantia nigra neurons. Neuron 62(2):218-229.
16. Ulusoy A, Björklund T, Buck K, Kirik D (2012) Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons. Neurobiol Dis 47(3):367-377.
17. Caudle WM, Colebrooke RE, Emson PC, Miller GW (2008) Altered vesicular dopamine storage in Parkinson's disease: A premature demise. Trends Neurosci 31(6):303-308.
18. Kirshner N (1962) Uptake of catecholamines by a particulate fraction of the adrenal medulla. Science 135(3498):107-108.
19. Kirshner N, Rorie M, Kamin DL (1963) Inhibition of dopamine uptake in vitro by reserpine administered in vivo. J Pharmacol Exp Ther 141:285-289.
20. Pettibone DJ, Totaro JA, Pflueger AB (1984) Tetrabenazine-induced depletion of brain monoamines: Characterization and interaction with selected antidepressants. Eur J Pharmacol 102(3-4):425-430. (Pubitemid 14064081)
21. Fon EA, et al. (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19(6):1271-1283. (Pubitemid 28030546)
22. Wang YM, et al. (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19(6):1285-1296.
23. Caudle WM, et al. (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27(30):8138-8148. (Pubitemid 47173329)
24. Taylor TN, Alter SP, Wang M, Goldstein DS, Miller GW (2014) Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76(Pt A):97-105.
25. Takahashi N, et al. (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94(18):9938-9943.
26. Rilstone JJ, Alkhater RA, Minassian BA (2013) Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med 368(6):543-550.
27. Simons CJP, van Winkel R; GROUP (2013) Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition. Schizophr Bull 39(4):848-856.
28. Solovieff N, et al. (2014) Genetic association analysis of 300 genes identifies a risk haplotype in SLC18A2 for post-traumatic stress disorder in two independent samples. Neuropsychopharmacology, 10.1038/npp.2014.34.
29. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B (2006) Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 15(2):299-305. (Pubitemid 43125983)
30. Brighina L, et al. (2013) Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease. Neurobiol Aging 34(6):1712.e9-1712.e13.
31. Chang H-Y, et al. (2006) Overexpression of the Drosophila vesicular monoamine transporter increases motor activity and courtship but decreases the behavioral response to cocaine. Mol Psychiatry 11(1):99-113. (Pubitemid 43251092)
32. Lawal HO, et al. (2010) The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons. Neurobiol Dis 40(1):102-112.
33. Sang TK, et al. (2007) A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J Neurosci 27(5):981-992.
34. Yorgason JT, España RA, Jones SR (2011) Demon voltammetry and analysis software: Analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. J Neurosci Methods 202(2):158-164.
35. Beninger RJ (1983) The role of dopamine in locomotor activity and learning. Brain Res 287(2):173-196.
36. Kaur D, et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease. Neuron 37(6):899-909. (Pubitemid 36398297)
37. Pothos EN, et al. (2000) Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci 20(19):7297-7306.
38. Pothos EN (2002) Regulation of dopamine quantal size in midbrain and hippocampal neurons. Behav Brain Res 130(1-2):203-207.
39. Colliver TL, Pyott SJ, Achalabun M, Ewing AG (2000) VMAT-mediated changes in quantal size and vesicular volume. J Neurosci 20(14):5276-5282. (Pubitemid 30457724)
40. Gong LW, Hafez I, Alvarez de Toledo G, Lindau M (2003) Secretory vesicles membrane area is regulated in tandem with quantal size in chromaffin cells. J Neurosci 23(21):7917-7921. (Pubitemid 37052360)
41. Patel J, Mooslehner KA, Chan PM, Emson PC, Stamford JA (2003) Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J Neurochem 85(4):898-910. (Pubitemid 36578622)
42. Travis ER, Wang YM, Michael DJ, Caron MG, Wightman RM (2000) Differential quantal release of histamine and 5-hydroxytryptamine from mast cells of vesicular monoamine transporter 2 knockout mice. Proc Natl Acad Sci USA 97(1):162-167. (Pubitemid 30055801)
43. Kahlig KM, Galli A (2003) Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 479(1-3):153-158. (Pubitemid 37377884)
44. Song H, et al. (1997) Expression of a putative vesicular acetylcholine transporter facilitates quantal transmitter packaging. Neuron 18(5):815-826. (Pubitemid 27232791)
45. Nagy PM, Aubert I (2012) Overexpression of the vesicular acetylcholine transporter increased acetylcholine release in the hippocampus. Neuroscience 218:1-11.
46. Kolisnyk B, et al. (2013) ChAT-ChR2-EYFP mice have enhanced motor endurance but show deficits in attention and several additional cognitive domains. J Neurosci 33(25):10427-10438.
47. Wilson NR, et al. (2005) Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1. J Neurosci 25(26):6221-6234. (Pubitemid 40923489)
48. Daniels RW, et al. (2004) Increased expression of the Drosophila vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease in quantal content. J Neurosci 24(46):10466-10474. (Pubitemid 39552631)
49. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455(7215):894-902.
50. Swerdlow NR, Koob GF (1987) Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striatopallido-thalamic function. Behav Brain Sci 10:197-208.
51. Nestler EJ, Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13(10):1161-1169.
52. Liu Y, et al. (1992) A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70(4):539-551.
53. Gainetdinov RR, et al. (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70(5):1973-1978. (Pubitemid 28207819)
54. Mooslehner KA, et al. (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism. Mol Cell Biol 21(16):5321-5331. (Pubitemid 32702438)
55. Ballester M, Castelló A, Ibáñez E, Sánchez A, Folch JM (2004) Real-time quantitative PCR-based system for determining transgene copy number in transgenic animals. Biotechniques 37(4):610-613. (Pubitemid 39391178)
56. Goldstein DS, et al. (2011) Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 18(5):703-710.
57. Kile BM, et al. (2012) Optimizing the temporal resolution of fast-scan cyclic voltammetry. ACS Chem Neurosci 3(4):285-292.
58. Fan X, Hess EJ (2007) D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD. Neurobiol Dis 26(1):201-211. (Pubitemid 46436498)